Quick Answer
AGIOS PHARMACEUTICALS, INC. reported Revenue (ASC 606) of $54.03 million for fiscal year 2025.
AGIOS PHARMACEUTICALS, INC. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $54.03M | +48.0% |
| 2024 | $36.50M | +36.1% |
| 2023 | $26.82M | +88.4% |
| 2022 | $14.24M | — |
| 2021 | $0.00 | — |
| 2020 | $0.00 | -100.0% |
| 2019 | $117.91M | +24.9% |
| 2018 | $94.39M | +119.4% |
| 2017 | $43.01M | -38.5% |
| 2016 | $69.89M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $12.88M | +43.7% | +3.4% |
| June 30, 2025 | $12.46M | +44.6% | +42.7% |
| March 31, 2025 | $8.73M | +6.6% | -2.7% |
| September 30, 2024 | $8.96M | +21.2% | +4.1% |
| June 30, 2024 | $8.62M | +28.4% | +5.2% |
| March 31, 2024 | $8.19M | +46.0% | +10.7% |
| September 30, 2023 | $7.40M | +110.4% | +10.2% |
| June 30, 2023 | $6.71M | +20.2% | +19.7% |
- AGIOS PHARMACEUTICALS, INC. showed an increase of +48.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, AGIOS PHARMACEUTICALS, INC.’s revenue (asc 606) has declined by 22.7% (from $69.89 million to $54.03 million).
- The most recent figure is from AGIOS PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: